Salt Lake City-based molecular diagnostic firm Myriad Genetics brings molecular genomic cancer testing to India.
According to the company, genomic tests are available for 9 cancers: breast, pancreatic, ovarian, endometrial, melanoma, prostate, colon, lung and gastric. “We are pleased to bring our 25 years of experience in clinical genetic testing to India,” said Gary King, Executive Vice-President of International Operations, Myriad Genetics. Gary further added that, “Indian patients can now access world leading tests such as BRAC Analysis to identify the risk of developing breast and ovarian cancer, Colaris™ for hereditary colorectal cancer and the myRisk test, which assesses the risk of developing eight cancers.
These tests screen for cancer risks and enable families of cancer patients to take preventive measures. All testing will be carried out at Myriad’s labs in U.S.A. and Germany.
